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Abstract M13 filamentous bacteriophage has been used in
displaying disease-specific antibodies, biomarkers, and pep-
tides. One of the major drawbacks of using phage in diagnos-
tic assays is the aspecific adsorption of proteins leading to a
high background signal and decreasing sensitivity. To deal
with this, we developed a genetically pure, exchangeable
dual-display phage system in which biomarkers and
streptavidin-binding protein (SBP) are displayed at opposite
ends of the phage. This approach allows for sample purifica-
tion, using streptavidin-coated magnetic beads resulting in a
higher sensitivity of signal detection assays. Our dual-display
cassette system approach also allows for easy exchange of
both the anchor protein (SBP) and the displayed biomarker.
The presented principle is applied for the detection of anti-
body reactivity against UH-RA.21 which is a good candidate
biomarker for rheumatoid arthritis (RA). The applicability of
dual-display phage preparation using a helper plasmid system
is demonstrated, and its increased sensitivity in phage ELISA
assays using patient serum samples is shown.
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Introduction
Phage display (PD) has taken its stand in the era of molecular
biology in the last two decades by displaying a large number
of proteins, antibodies, amino acids, etc. on the surface of
phage (Reynolds et al., 2011; Soendergaard et al., 2011). The
non-lytic M13 filamentous phage is a single-stranded (ss)
DNA virus that infects a number of gram-negative bacteria.
A phage particle consists of a long cylindrical protein struc-
ture, 800–900 nm in length and 6.5 nm in diameter. It has one
major coat protein, pVIII, that surrounds the entire phage body
with 2,700 copies, and each end has two minor coat proteins
(pVII, pIX and pVI, pIII), each present in 3–5 copies. All these
coat proteins contribute to the stability of the phage (Sidhu,
2001; Sidhu, 2000; Arap 2005). The phage genome carries the
genes for these five coat proteins and the genes for the proteins
involved in phage replication. PD involves the fusion of a
foreign peptide or protein with a minor or major coat protein
of the phage through genetic recombination of the phage
genome with the complementary deoxyribonucleic (cDNA)
of the insert, resulting in the phage particle displaying the
peptide or protein fused to the coat protein, and also
possessing the gene of the protein insert, providing a direct
link between the phenotype and the genotype (Dover et al.
2009).
Between the two popular vector systems, using a phagemid
vector system to produce functional phage particles is better
than using a phage vector, showing a good display level of the
fusion protein, and being genetically more stable in displaying
larger proteins (Sidhu, 2001). However, a phagemid vector
carries only the gene for the coat protein to which the cDNA
of the protein of interest is fused. So, after transformation of
the bacterial host with phagemid, it needs a coinfection from a
helper phage to provide the native genes for all the other
structural proteins to make a complete and functional phage.
The genome of the helper phage lacks a packaging signal, so
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the genome of the phagemid vector will preferentially get
packaged into the new phage particles, retaining the link
between the phenotype and the genotype of the phage (Qi
et al. 2012; Bratkovic, 2009). Chasteen and coworkers pro-
posed a different vector system as an alternative to the use of
helper phage, making use of helper plasmids, providing mul-
tivalent display and genetically pure phage (Chasteen et al.
2006). As with the helper plasmid/phagemid vector system,
phage produced by this method contains only the genome of
the phagemids. Although a dual-display system in T4 phage
using bipartite SOC-HOC system and lambda phage is attrac-
tive because this allows for a higher copy number and there is
no need for secretion through the cell membrane; most of the
biomarkers (C DNA libraries) have been developed from
M13-based phagemid system (Ren and Black 1998; Ren
et al. 1996; Pavoni et al. 2013). Moreover, the RA biomarkers
that are addressed in this work have also been selected using
the M13 phage display system. Therefore, we aim at the
development of a new strategy to improve the sensitivity of
already available biomarkers and possibly taking into sensing
platform.
Protein aggregation and lack of protein transfer to the
bacterial periplasm are often observed and result in the failure
of phage display. This problem can be addressed by the
introduction of a leader peptide or signaling peptide into the
fusion protein. However, the correct folding can be compro-
mised due to the secretion of the phage from the host
(Velappan et al. 2010). Therefore, coat proteins pVIII and
pIII are commonly used for protein display because those
genes contain N-terminal periplasm-directing signal se-
quences. By introducing such a signal sequence between the
N-terminus of pVII or pIX and the cDNA of the protein of
interest, it becomes possible to develop a stable display system
using those coat proteins as well (Georgieva and Konthur
2012; Loset and Sandlie 2012). There is a persisting demand
for suitable disease-related biomarkers as indicators for dis-
eases, like proteins, peptides, metabolites, and antibodies
(Vithayathil et al. 2011). The capability to display disease-
specific proteins on a phage surface could be a big advantage
in the field of diagnostics. Phage can be directly used as a
probe when it is modified to display disease-related antigens
on its surface (Kierny et al. 2012). Also, problems associated
with synthesizing small molecules can be overcome by PD
(Dudak et al. 2011). This would involve the phage in the
development of diagnostic biosensors, functioning as a
receptor, attached to an electrode or transducer surface.
Increasing attention has been drawn towards the use of
phage as a receptor molecule in different applications,
due to its inherent stability and resistance to denatur-
ation in unfavorable conditions, unlike DNA and anti-
bodies. It can sustain higher temperatures of up to
70 °C and pH variations from 2.5 to 12 (Arap 2005;
Mao et al. 2009).
Phage production is also cost-effective, in contrast to the
production of monoclonal antibodies. They can be produced
in sufficient numbers by just infecting a bacterial host. Phage-
based assays are mostly performed in an ELISA format;
however, if complex substances such as serum are used in
detecting targets, this approach lacks sensitivity due to
aspecific binding of interfering serum components increasing
the background signal. The same problem can be expected in
the abovementioned biosensor setups. Therefore, sample
preparation should also be taken into account when setting
up such assays.
The design of a dual-display system, where phage displays
both a biomarker and a capturing protein, allows for such a
sample preparation. In the presented approach, the dual-
display phage will display a biomarker fused to pVI at one
end and an anchoring streptavidin-binding protein (SBP)
fused to pVII at the other end of the phage. SBP will be
binding to streptavidin-coated magnetic beads allowing a
magnetic capturing of the phage. As a proof of principle, a
candidate biomarker for rheumatoid arthritis (RA) UH-RA.21
(Somers et al. 2011; Somers et al. 2005) is used to screen for
the presence of autoantibody reactivity in the serum of RA
patients in comparison to basic ELISA procedures.
Materials and methods
Vectors and minigene
M13cp helper plasmid with chloramphenicol (Chlr) resistance
in a DH5αF′ bacterial host was kindly provided by ARM
Bradbury’s lab (Las Alamos, USA) (Chasteen et al. 2006).
pspBRA21 phagemids and pspB empty phagemids with Amp
resistance in TG1 bacterial hosts (Somers et al. 2009) and
serum samples with different levels of RA autoantibodies
(highly positive, moderately positive, borderline positive) as
well as healthy control serum samples were produced in-
house. Helper phage with kanamycin (Kan) resistance was
purchased from GE healthcare (Diegem, Belgium).
Ampicillin-resistant IDTB vector containing SBP minigene
gVII-SBP was purchased from IDT (Leuven, Belgium). For
plasmid and phagemid purification from host bacterial cells,
Qiagen midi prep kit from Qiagen (Antwerp, Belgium).
gVII-SBP minigene cloning into the genome of the M13cp
helper plasmid
Restriction enzymes SnaB I and Bsp 1407I (TaKaRa Bio Inc
(Japan)) were used to replace the gVII of the helper plasmid
with the SBP minigene. Five microliters of ligation product
was then transformed into a freshly prepared chemically com-
petent DH5αF′ bacterial strain, by subjecting the bacteria to a
heat shock at 42 °C for 30 s, after which they were plated on
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LB agar (Invitrogen, Ghent, Belgium) plates with 15 μg/ml of
the antibiotic Chlr and incubated at 37 °C overnight. A neg-
ative control was also prepared where the DH5αF′ bacterial
strain was transformed with unmodified M13cp. DH5αF′
cells already containing the Chlr-resistant M13cpSBP or
M13cp helper plasmid were prepared to be competent and
cotransformed with Amp-resistant phagemid pspB, either
empty (pspB) or bearing the cDNA of the autoantigenic target
RA21 fused to its pVI gene (pspB RA21), in the same way as
with the helper plasmid. The newly cotransformed DH5αF′
colonies were plated in 2×YT media (BD (Erembodegem,
Belgium)) containing 15 μg/ml of Chlr and 100 μg/ml of
Amp.
Colony PCR and sequencing
Positive colonies grown in the antibiotic selective plates were
used in colony PCR with the forward primer 5′-AAT GTT
GTT CCG TTA GTT CG-3′ and reverse primer 5′-CCATTA
AAC GGG TAA AAT AC-3′ (Eurogentec (Seraing,
Belgium)) for helper plasmid transformed with SBP
minigene, and the primer sets gVI forward primer 5′-TTA
CCC TCT GAC TTT GTT CA-3′ and pUC 19 reverse primer
5′-CGC CAG GGT TTT CCC AGT CAC GAC-3′ were used
for phagemids. The thermocycling conditions included an
initial denaturation at 95 °C for 7 min, followed by 30 cycles
comprising of a 30-s denaturation step at 95 °C, a 30-s
annealing step at 55 °C, and a 4-min elongation step at
72 °C, and one final elongation step carried out at 72 °C for
10 min. These PCR products have been used without any
further purification in sequencing with the same forward
primers as mentioned above by using ABI PRISM Genetic
Analyzer 310 (Applied Biosystems (Warrington, UK)). The
sequences were analyzed using Chromas software version
2.13 and DNAMAN version 7.0.
Phage production
Dual SBP-RA21 and single SBP or UH-RA.21 display phage
were produced from the double transformed DH5αF′ bacterial
cells. A single colony from the plate was picked and grown
until they attained an exponential growth rate in 2×YT medi-
um containing 15μg/ml of Chlr and 100μg/ml of Amp. Then,
4 ml of exponentially growing cells was transferred into 50 ml
of fresh 2×YT broth medium with both antibiotics.
Subsequently, they were incubated in a shaking incubator at
200 rpm for 16 to 18 h at 31 °C. Afterwards, all the bacterial
cells were pelletized by centrifuging at 4,000 rpm, and then,
the supernatant was added with 20 % 6000 MW PEG (Merck
(Darmstadt, Germany)) in 2.5 M NaCl and kept on ice for 1 h.
They were centrifuged again at 4,000 rpm for 20 min. The
obtained white phage pellets were washedwith 1 × phosphate-
buffered saline (PBS) until all the remaining bacterial cells
were removed.
In addition, to produce positive control phage, Std21, TG1
bacterial cells bearing the phagemid pspB RA21 were grown
up to the exponential phase, and 10ml of exponentially grown
cells was added with 5 μl of M13KO7 helper phage. The
helper phage was allowed to infect the TG1 cells for 30 min in
a 37 °C water bath, and the solution was then incubated in a
shaking incubator for 10 min at 100 rpm while keeping the
same temperature. These infected cells were added to fresh
2×YT medium containing 100 μg/ml Amp and 40 μg/ml Kan
and grown overnight at 30 °C. After the phage production, the
amount of phage was tittered by using PR phage titration kit
(Progen Biotechnik GmbH (Germany)). The absorbance
values of phage samples were extrapolated with the standard
graph made from the absorbance values of the known phage
standards from the kit.
Phage ELISA
In order to check the SBP display, ELISA microtiter plates
(Greiner Bio-One BVBA, Wemmel, Belgium) were coated
overnight with 5 μg/ml anti-pVIII antibodies. In the finding of
RA21 display and dual expression at the same time, ELISA
microtiter plates were coated overnight with 10 μg/ml anti-
human IgG antibodies (Dako, Denmark) as mentioned in
Table 1. Afterwards, the plates were washed twice with 1×
PBS. Then, the wells were blocked with 5 % Marvel skim
milk powder (Chivers, Dublin Ireland) in 1×PBS (MPBS) for
2 h at 37 °C while shaking. The plates were washed three
times with 1×PBS containing 0.1 % of between 20 (PBST)
and once with 1×PBS. Simultaneously, all the phage samples
were diluted to 1012 colony-forming units (CFU)/ml in 5 %
MPBS.
In order to confirm the RA21 and dual expression, 100 μl
of 1×1012 CFU/ml of phage in 5 % MPBS was first pre-
incubated with 100 μl of 100-fold in 5 % MPBS diluted RA
patient’s serum with different levels of anti-RA21 autoanti-
bodies (highly positive, moderately positive, borderline posi-
tive, and negative (healthy control)) at 37 °C for 30 min under
static conditions and for 30 min while shaking at 100 rpm. For
the evaluation of dual expression, 1 μl of 10 μg/μl (3–6×106)
streptavidin-coated magnetic beads (Invitrogen, Ghent,
Belgium) was added to the phage-serum mixture and incubat-
ed again at 37 °C for 30 min while shaking. The phage-serum-
bead complexes were captured with a magnetic field, and
washed twice with 5 % MPBS to remove unbound phage or
remaining serum, and resuspended in 5 % MPBS.
For SBP display confirmation, 100 μl of pure 1012 CFU/ml
phage was added to the wells. For confirmation of RA21
expression, 100 μl of the pre-incubated phage and serum
samples were added to the wells. For dual expression study,
100 μl of the pre-incubated phage/serum/bead complex was
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added to the wells. They were incubated for 1 h under
static conditions and for 30 min while shaking at 37 °C.
After washing the titer plate as described above,
0.83 μg/ml of a streptavidin-horseradish peroxidase
(HRP) conjugate was added for the detection of SBP,
and incubated for 1 h at RT while shaking. For the
studies of RA21 and dual expression, polyclonal anti-
M13 antibodies conjugated with HRP from the phage
titration kit were added as secondary antibodies and
incubated for 1 h at RT while shaking. After washing,
ready-to-use TMB and H2O2 (Thermo Scientific
(Erembodegem, Belgium) were used as a substrate so-
lution for HRP, inducing a color reaction, and 2 M
H2SO4 was used as a stop solution. The plate was read
at a wavelength of 450 nm to get the absorbance
values.
Dot blotting
Different 5 μl spots with 1013 CFU/ml of phage were applied
to a WhatMan nitrocellulose membrane filter paper
(WhatMan GmbH, Germany). The spots were allowed
to dry for 15 min, and then, the surface was blocked
with 5 % MPBS for 15 min. After rinsing two times in
1×PBS, the nitrocellulose filter paper was treated with
0.83 μg/ml of streptavidin-HRP for 1 h at RT while
shaking. The paper was washed three times with 1×PBS
containing 0.5 % Triton™ X-100 and twice with 1×
PBS. Finally, fresh DAB and H2O2 (Thermo Scientific
(Erembodegem, Belgium) solution was added to develop
the colored spots.
Statistical analysis
Statistical analysis was performed using a trial version of
GraphPad InStat version 3.1. Non-parametric ANOVA
(Kruskall-Wallis testing) and Dunn’s multiple comparison
tests were used to compare the reactivity against the serum
samples with the different levels of anti-UH-RA.21 pos-
itivity. The levels of statistical significance were as
follows: a P value of <0.05 (*), a P value of <0.01 (**),
and a P value of <0.001 (***).
Results
Construction of the M13cpSBP helper plasmid
Displaying proteins, such as SBP in this case, on pVII is
feasible but only if the cDNA of the insert is placed between
the gVII start codon and a signaling or a leader peptide (Loset
and Sandlie 2012; Kierny et al. 2012). Figure 1 shows the
design and construction of the helper plasmid M13cpSBP.
The most common signaling peptide PelB is used to ensure
the correct folding of SBP and its transport to the bacterial
membrane, and eventual ly to the phage surface
(Kwasnikowski et al. 2005). A predesigned SBP minigene
consisting of the cDNA of the signaling peptide sequence
PelB and the cDNA of SBP is inserted upstream of the start
codon of gVII of the helper plasmid M13cp (Fig 1). This SBP
minigene was designed between two restriction sites SnaB I
and Bsp1407I which allows easy insertion into the gVII of the
wild-type helper plasmid M13cp. In addition to this, the
coding sequence of the anchor peptide SBP itself is flanked
with two different restriction sites Not I and Mfe I, which
makes SBP easily interchangeable with another type of an-
choring peptide. The resulting SBP modified helper plasmid
was termed M13cpSBP, and it was transformed into a DH5αF′
bacterial host. As a negative control, unmodified helper plas-
mid M13cp was also transformed.
After transformation, successful insertion of the SBP
minigene into the helper plasmid M13cp was confirmed by
colony PCR and sequencing. Figure 1 insert shows the
∼100 bp longer fragment of M13cpSBP (lane 2) as compared
to unmodified M13cp (lanes 3–4); the sequence of the
resulting construct shown in Fig. 1 was confirmed by sequenc-
ing analysis.
M13cpSBP and wild-type phage production
In order to produce phage particles, a helper plasmid always
needs support from a phagemid, since a helper plasmid lacks a
packaging mechanism. So, Dh5αF′ cells bearing either mod-
ified M13cpSBP or unmodified M13cp helper plasmid were
cotransformed with pspB carrying UH-RA.21 and pspB
phagemids (Somers et al. 2011) without insert (empty
phagemid) and plated on 2×YT plates containing
Table 1 Components of phage ELISA
Target assay Coating antibody Sample Detection antibody/entity
SBP Anti-M13 Phage Streptavidin HRP
UH-RA.21 Anti-human IgG Pre-incubated phage and serum Anti-M13 HRP
Dual display Anti-human IgG Pre-incubated phage serum and streptavidin bead Anti-M13 HRP
This table comprises the different assays and their coating antibodies, nature of sample, and detection antibodies used
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chloramphenicol (Chlr) and Amp. These antibiotics are used
to select bacteria containing both helper plasmid (with and
without SBP) and phagemid (with and without UH-RA.21). A
schematic overview of the cotransformation and phage pro-
duction procedure is shown in Fig. 2. Chlr- and Amp-resistant
cells were subjected to colony PCR, and the resulting products
were analyzed by gel electrophoresis (Fig. 3a). The colony
PCR products show the additional 600 bp in the SR21 phage
(lanes 2–4) corresponding to the UH-RA.21 marker, as com-
pared to the SB phage (lanes 5–7). Sequencing analysis
(Fig. 3b) confirmed the sequences of RA21 (Somers et al.
2011). One of the confirmed positive SR21 colonies con-
taining the two targets SBP and RA21 was selected for
phage production in 2×YT medium. This helper
plasmid-mediated phage production leads to genetically
pure phage because the M13cp helper plasmid does not
have any packaging signal and delivers only proteins.
The phagemid genome carrying the gVI-RA21 cDNA is
preferably packed into each phage (Chasteen et al.
2006). Titer values of all the phage particles produced
range from 1×1013 to 5.5×1013 CFU/ml.
In this way, four different phage samples were prepared
using this approach as is summarized in Table. 2. The standard
positive control phage (Std21), which has been used previ-
ously in conventional phage ELISA protocols (Somers et al.
2011), is prepared differently by infecting a bacterial host
containing UH-RA.21 in pspB phagemids with helper phage
M13, results in phage displaying RA21 at pVI of the phage
and contains other wild-type proteins from helper phage M13.
Evaluation of the expression of SBP in pVII display phage
Theoretically, phage SR21 and SB should display SBP on all
five copies of the coat protein pVII of the phage particle, due
to the lack of native gVII in the pspB phagemid. Moreover,
SBP can be displayed at a higher local concentration due to
the small size of pVII and the tightly packed system
(Kwasnikowski et al. 2005).
This is evident from the immediate strong color formation
in a dot blotting experiment, as shown in Fig. 4a. Among the
five different phage preparations, the dual-display phage
SR21 and one of the single display phage, SB, are positive,
Fig. 1 Construction of the helper plasmid M13cpSBP. A minigene was
constructed in which PelB (purple) and SBP (red) coding sequences are
inserted upstream of the gVII gene of wild-type M13cp phage DNA. The
SBP sequence is flanked by the restriction sitesNot I andMfe I. The entire
gVII-SBP minigene is located between gV and gIX and is contained
between the restriction sites SnaBI and Bsp1407I. Figure 1 insert—A
1 % agarose gel demonstrates the successful insertion of SBP and PelB
into gVII of M13cp. Lane 1, 100 bp ladder; lane 2, recombinant
M13cpSBP construct; lanes 3 and 4, wild-type M13cp; and lane 5,
negative control. Sequencing of the M13cpSBP confirmed the in-frame
insertion of the SBP and pelB sequences as shown in the presented
sequence
Fig. 2 Graphical representation of the cotransformation and resulting
phage preparation DH5αF′ host bacteria, containing the M13cpSBP or
M13cp helper plasmid, were cotransformed with UH-RA.21
autoantigenic target bearing or empty phagemid. Bacteria containing both
plasmids were grown in 2×YT medium to produce phage particles
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while the other phage types remain negative. This was con-
firmed in a phage ELISA format, as shown in Fig. 4b, in
which SR21 and SB show a six-fold absorbance compared to
the negative phage CR21 and CB. As a control in both
experiments, phage produced from the cotransformation of
DH5αF′ with SBP-negative helper phage and pspB carrying
RA21, referred to as Std21, was also checked for SBP expres-
sion, and was found to be negative for SBP expression.
Screening of RA patient sera using UH-RA.21 displaying
phage
As a proof of concept, we have used one of the most promis-
ing RA autoantigenic targets RA21 which was displayed on
pVI of the filamentous phage M13 (Somers et al. 2009;
Somers et al. 2011). The expression of RA21 was evaluated
in phage ELISA using the sera from RA patients who were
classified according to the amount of autoantibodies present in
their serum (either highly positive, moderately positive, or
borderline positive), and serum from healthy controls who
are negative for anti-RA21 autoantibodies. These sera were
allowed to react with the five types of phage displaying UH-
RA.21 (SR21, CR21, Std21) or not displaying (SB, CB) UH-
RA.21. Autoantibodies and phage complexes were captured
onto anti-human IgG-coated ELISA plates. Anti-M13 (anti-
pVIII) polyclonal antibodies conjugated with HRP were used
as detection antibodies in a sandwich ELISA protocol.
Figure 5 shows the ELISA results of the Std21 phage prepa-
rations, which is used in a standard phage ELISA protocol to
the single (CR21) and the dual-display phage (SR21). Both
CR21 and SR21 show high levels of absorbance in the phage
ELISAwhen treated with serum from highly, moderately, and
borderline positive patients for anti-RA21 autoantibodies.
This is comparable to the standard ELISA procedure using
Std21 phage. All three phage types (SR21, CR21, and
Std21), however, were not able to distinguish the bor-
derline positive sera from the negative control sera
significantly. Nevertheless, our dual-display phage sys-
tem did not interrupt the display of UH-RA.21 and
performs well in phage ELISA, comparable to Std21
phage used up to now. This confirms the expression
of the UH-RA.21 marker in our phage preparations.
Fig. 3 Cotransformation of DH5αF′ cells with pspB phagemids. a 1 %
agarose gel demonstrating the difference of ∼600 nucleotides, corre-
sponding to the 28 amino acids of the UH-RA.21 marker and the linker
sequences between the dual-display phage SR21 (lanes 2, 3, and 4) and
the single-display phage SB (5, 6, and 7). Lane 1 shows the result of the
colony PCR for RA21 performed on DH5αF’ bacteria cotransformed
with native pspB. b Sequence analysis confirms the in-frame sequences
of RA21 and its translation product is shown
Table 2 Types of phage produced and protein displayed and its titer
Name of the phage Displayed protein Titer in CFU in 1013





The first four phages are the different types of phage produced using
phagemid and helper plasmid system. Std21 is the conventional phage
prepared and used as a positive control in phage ELISA
Fig. 4 Expression of SBP in pVII in displaying phage. The expression of
SBP was analyzed in four types of phage (SR21, SB, CR, and CB)
produced through the helper plasmid/phagemid system and compared
to phage (Std21) produced through the helper phage/phagemid system. a
Dot blot shows the four types of phage and the Std21 phage on a
nitrocellulose paper, using a SBP-dependent color reaction. b Phage
ELISA on anti-pVIII-coated plates, treated with the four types of phage
and the Std21 phage, and detected with a streptavidin-conjugated HRP
and a TMB-dependent color reaction
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Screening RA patients sera for UH-RA.21 autoantibodies
after sample purification based on dual-display phage
The five types of phage were again pre-incubated with the sera
from RA patients containing different levels of anti-UH-
RA.21 antibody positive (highly positive, moderately posi-
tive, and borderline positive) and with anti-RA21-negative
sera from healthy controls, to allow recognition of the
displayed RA21. The phages with and without bound serum
autoantibodies were subsequently isolated with streptavidin-
coated magnetic beads, binding to the displayed SBP. These
complexes of phage and serum autoantibodies captured on
streptavidin-coated magnetic beads were then added to anti-
human IgG-coated ELISA plates and detected with anti-M13
antibodies conjugated with HRP. All phages displaying SBP
are bound to and isolated by the magnetic beads. However, of
those, only the one displaying RA21will bind to the microtiter
plate through an anti-RA21/anti-human IgG complex, and
generate a color reaction. Figure 6 shows very clearly that
dual-display phage SR21 which is pre-incubated with the
positive sera can specifically bind to the autoantibodies in
the serum with its pVI-displayed UH-RA.21 autoantigenic
target and also to the streptavidin-coated magnetic beads by
its pVII-displayed SBP at the same time, and generate a
positive ELISA result. This dual-display system allows mag-
netic capture of phage complex and allows specific selection
of dual-display phage in assays, that gives higher sensitivity.
Moreover, the absorbance values for the borderline positive
sera still increased significantly as compared to the negative
serum. In other words, using a dual-display phage system, a
higher sensitivity is reached in RA diagnosis, allows specific
detection of an additional group of patients, displaying only
low amounts of anti-UH-RA.21 autoantibodies. Since these
patients could still be in an early stage of the disease, this
could have tremendous impact on prognosis.
Discussion
In a previous work, Somers et al. (2009) and Somers et al.
(2011) have identified a panel of 14 autoantigenic targets for
RA in a pVI-displayed cDNA library using SAS technology.
One of these 14 biomarkers, UH-RA.21 shows a high sensi-
tivity to detect early RA patients who are rheumatoid factor-
negative (RF−) and anti-cyclic citrullinated peptide (ACCP−)
negative (Somers et al. 2009). This biomarker was chosen as a
proof of principle target in this study. In order to increase the
assay sensitivity, we introduced a short SBP peptide
(HFNTHPQ) into the gene VII (gVII) of the helper plasmid,
which contains a his-pro-glu (HPQ) motif that allows strong
streptavidin binding (Dudak et al. 2011; Kwasnikowski et al.
2005; Chen et al. 2004). It is a very strong natural non-
covalent coupling with a dissociation constant of ∼2.5×
108M (Chen et al. 2004). In this report, we have demonstrated
Fig. 5 Screening RA patient sera for the presence of autoantibodies with
RA21 displaying phage preparations. All four types of phage (SR21,
CR21, SB, and CB) were produced through the helper plasmid/phagemid
system as compared to phage (Std21) produced through the helper phage/
phagemid system by phage ELISA. The four types of phage and the
Std21 phage were pre-incubated with serum that was highly positive
(blue), moderately positive (red), borderline positive (green), and nega-
tive (violet) for antibody reacting against UH-RA.21 and captured onto
anti-human IgG-coated ELISA plates. SR21, CR21, and Std21 were able
to discriminate highly and moderately positive serum from negative
serum by showing an increased absorbance at 450 nm. However, dis-
crimination between borderline positive and negative serum was not
possible. The statistical comparison of the phage ELISA results among
the sera with different levels of autoantibody positivity has been given in
the form of stars (*/**/***) which corresponds to the approximate P
values of P<0.05 (significant), P<0.01(good significant), and P<0.001
(excellent significant) respectively. This experiment was carried out three
times, with each condition in duplicate
Fig. 6 Screening RA patients sera for UH-RA.21 autoantibodies after
sample purification based on dual-display phage: All four types of phage
(SR21, CR21, SB, and CB) produced through the helper plasmid/
phagemid system, as compared to phage produced through the helper
phage (Std21) system by phage ELISA. The four types of phage and the
Std21 phage were pre-incubated with serum that was highly positive
(blue), moderately positive (red), borderline positive (green), and nega-
tive (violet) for anti-UH-RA.21, and isolated with streptavidin-coated
magnetic beads. The resulting complexes were captured onto anti-human
IgG-coated ELISA plates. The statistical comparison of the phage ELISA
results among the sera with different levels of autoantibody positivity is
shown in which */**/*** which corresponds to approximate P values of
P<0.05 (significant), P<0.01(good significant), and P<0.001 (excellent
significant), respectively. These experiments were carried out three times,
with each condition in duplicate
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a novel approach to produce a dual-display phage, displaying
a disease-related biomarker for screening at one end of the
phage, and an anchor peptide for attachment to a sensing
platform at the other end, for an easy, rapid, and cost-
effective way of diagnosis. In order to achieve this,
cotransformation of bacterial host cells with a phagemid vec-
tor providing the autoantigenic target UH-RA.21 and with a
helper plasmid providing the anchoring peptide SBP was
performed. This SBP was fused with a leader peptide pelB,
at the pVII of helper plasmid M13cp. The resultant phage
displayed the autoantigenic target UH-RA.21 at one end and
SBP at the other end.
Four different types of phage displaying, both UH-RA.21
and SBP (SR21), either UH-RA.21 (CR21) or SBP (SB), and
non-displaying (CB) were produced by cotransforming helper
plasmids bearing bacterial cells with phagemid. And the con-
ventional positive control phage Std21 is produced via helper
phage, and phagemid system (Std21) was used to compare the
efficiency of different RA21 displaying phage. The SBP end
of a phage will allow capture of the phage in a well-oriented
fashion on a streptavidin-functionalized sensor surface by
forming strong affinity bonds or on magnetic beads allowing
for the isolation of autoantibodies from the serum of a patient.
At the same time, the other end of the phage is readily
available to screen for the autoantibodies in the patient’s
material.
Phage ELISA and dot blotting has been used in character-
izing the display of SBP, and the results confirms the clear
expression of SBP in both SR21 and SB phage from few-fold
higher absorbance compared to the other phage samples in
ELISA and immediate strong color formation in dot blotting.
Phage ELISA was also used to characterize the displaying
capacity of UH-RA.21 in three phage samples RA21, CR21,
and positive control phage Std21. As in standard ELISA
procedures, all show higher absorbance in phage ELISAwith
the patient’s serum samples although it is not significantly
discriminating the borderline positive serum from negative
control (healthy control).
However, using our dual-display approach sample purifi-
cation process using streptavidin-coated magnetic beads can
be used to isolate autoantibodies in the serum selectively by
the phage displaying UH-RA.21 and SBP. In addition, it was
shown that the optimal use of dual-display phage in the
screening for anti-RA21 autoantibodies in patient sera is
resulting in an increased assay sensitivity. Even patients that
are borderline positive for the presence of autoantibodies, and
that could not be discriminated from healthy controls using
regular phage ELISA approaches, show a significant increase
in absorbance, and can be clearly discriminated from healthy
controls. Moreover, this system is designed as a cassette-setup
to allow the exchange of SBP with any other anchoring
peptide and UH-RA.21 with any other biomarker depending
on varying needs. In the future, this dual-display phage can be
used as a receptor attached to a sensing platform for rapid
screening, making a label-free and highly specific diagnosis of
RA and other diseases possible.
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